Prescient Therapeutics Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume537,831 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

Receive PTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Prescient Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Prescient Therapeutics

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. Prescient Therapeutics Limited has a collaboration agreement with Carina Biotech to develop cell therapies. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in South Melbourne, Australia.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.96 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Prescient Therapeutics (ASX:PTX) Frequently Asked Questions

What stocks does MarketBeat like better than Prescient Therapeutics?

Wall Street analysts have given Prescient Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Prescient Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Prescient Therapeutics' key executives?

Prescient Therapeutics' management team includes the following people:
  • Mr. Yatomi-Clarke Steven Lee, MD, CEO & Director
  • Ms. Melanie Jaye Leydin C.A., B.Bus, CA, CFO & Company Sec. (Age 48, Pay $114k)
  • Dr. Terrence G. Chew, Chief Medical Officer (Age 74, Pay $155.99k)
  • Dr. James D. Winkler, Head of Bus. Devel. (Age 66)

Who are some of Prescient Therapeutics' key competitors?

What other stocks do shareholders of Prescient Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prescient Therapeutics investors own include SkyCity Entertainment Group (SKC) and Finders Resources (FND).

What is Prescient Therapeutics' stock symbol?

Prescient Therapeutics trades on the ASX under the ticker symbol "PTX."

How much money does Prescient Therapeutics make?

Prescient Therapeutics has a market capitalization of $0.00 and generates $1.19 million in revenue each year.

How many employees does Prescient Therapeutics have?

Prescient Therapeutics employs 171 workers across the globe.

What is Prescient Therapeutics' official website?

The official website for Prescient Therapeutics is

Where are Prescient Therapeutics' headquarters?

Prescient Therapeutics is headquartered at 10 North Park Place, Morristown, NJ 07960.

How can I contact Prescient Therapeutics?

Prescient Therapeutics' mailing address is 10 North Park Place, Morristown, NJ 07960. The company can be reached via phone at 61 3 9692 7222.

This page was last updated on 9/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.